SCHEMBL268337

SCHEMBL268337

COc1cc(OC)cc(C(=O)Nc2ccc(Br)cc2C(=O)N/N=C/c2cccc(F)c2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.49
MAPT P10636 4/20 0.49
LMNA P02545 2/20 0.49
ALDH1A1 P00352 2/20 0.49
SMN1; SMN2 Q16637 7/20 0.48
KMT2A Q03164 5/20 0.48
MEN1 O00255 3/20 0.48
KDM4E B2RXH2 3/20 0.48
NPSR1 Q6W5P4 2/20 0.48
PKM P14618 2/20 0.48
ALOX12 P18054 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
RAB9A P51151 7/20 0.47
NPC1 O15118 6/20 0.47
CTDSP1 Q9GZU7 3/20 0.47
SLC34A2 O95436 1/20 0.47
SLC34A1 Q06495 1/20 0.47
SLC34A3 Q8N130 1/20 0.47
SLC20A1 Q8WUM9 1/20 0.47
TDP1 Q9NUW8 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL268338 1.00 HPGD (0.49) HPGDMAPTLMNAALDH1A1SMN1; SMN2
SCHEMBL266429 0.91 SMN1; SMN2 (0.52) HPGDMAPTLMNAALDH1A1SMN1; SMN2
SCHEMBL266430 0.91 SMN1; SMN2 (0.52) HPGDMAPTLMNAALDH1A1SMN1; SMN2
SCHEMBL268976 0.90 RAB9A (0.58) HPGDMAPTALDH1A1SMN1; SMN2KMT2A
SCHEMBL268977 0.90 RAB9A (0.58) HPGDMAPTALDH1A1SMN1; SMN2KMT2A
SCHEMBL267176 0.90 MAPT (0.55) HPGDMAPTLMNAALDH1A1SMN1; SMN2
SCHEMBL267177 0.90 MAPT (0.55) HPGDMAPTLMNAALDH1A1SMN1; SMN2
SCHEMBL265436 0.89 MAPT (0.49) HPGDMAPTLMNAALDH1A1SMN1; SMN2
SCHEMBL265435 0.89 MAPT (0.49) HPGDMAPTLMNAALDH1A1SMN1; SMN2
SCHEMBL267637 0.89 MAPT (0.60) HPGDMAPTLMNAALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 HPGD 2509/4885MAPT 4195/4885LMNA 2001/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 HPGD 2407/4885MAPT 4648/4885LMNA 1925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.